Halozyme Therapeutics Long-Term Debt | HALO

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Halozyme Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
2.14 B	1.51 B	1.5 B	1.49 B	787 M	397 M	383 M	34.9 M	125 M	199 M	28 M	49.9 M	49.8 M	29.7 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.14 B	28 M	623 M

Quarterly Long-Term Debt Halozyme Therapeutics

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.94 B	1.94 B	800 M	1.51 B	1.51 B	1.51 B	1.5 B	1.5 B	1.5 B	1.5 B	1.5 B	1.5 B	1.49 B	1.49 B	1.49 B	1.15 B	788 M	787 M	786 M	786 M	785 M	-	-	-	-	383 M	383 M	383 M	383 M	34.9 M	34.9 M	34.9 M	34.9 M	125 M	125 M	125 M	125 M	199 M	199 M	199 M	199 M	28 M	28 M	28 M	28 M	49.9 M	49.9 M	49.9 M	49.9 M	49.8 M	49.8 M	49.8 M	49.8 M	29.7 M	29.7 M	29.7 M	29.7 M	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.94 B	28 M	592 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	10.9 M	$ 51.0	1.83 %	$ 1.48 B	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
Black Diamond Therapeutics BDTX	15.1 M	$ 1.88	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	437 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	13.9 M	-	-	$ 401 M	USA
Evelo Biosciences EVLO	43.6 M	-	-14.46 %	$ 27.9 M	USA
BioMarin Pharmaceutical BMRN	436 K	$ 60.26	0.06 %	$ 11.6 B	USA
BioNTech SE BNTX	185 M	$ 98.52	0.24 %	$ 23.8 B	Germany
Can-Fite BioPharma Ltd. CANF	15 K	$ 2.17	0.46 %	$ 3.57 M	Israel
Freeline Therapeutics Holdings plc FRLN	3.26 M	-	-	$ 384 M	Britain
Genocea Biosciences GNCA	4.15 M	-	-15.0 %	$ 3.04 M	USA
Catalyst Biosciences CBIO	303 K	$ 13.99	0.84 %	$ 1.25 B	USA
C4 Therapeutics CCCC	53.6 M	$ 2.98	0.3 %	$ 247 M	USA
Codexis CDXS	40.1 M	$ 1.32	1.09 %	$ 115 M	USA
Amryt Pharma plc AMYT	4.05 M	-	-	$ 621 M	Britain
Cerus Corporation CERS	10.2 M	$ 2.62	0.38 %	$ 499 M	USA
G1 Therapeutics GTHX	50 M	-	-	$ 370 M	USA
Coherus BioSciences CHRS	1.46 M	$ 1.13	0.43 %	$ 132 M	USA
Celldex Therapeutics CLDX	784 K	$ 31.1	1.16 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	2.03 M	$ 4.25	3.16 %	$ 51.9 M	Israel
Cellectar Biosciences CLRB	309 K	$ 1.8	0.72 %	$ 4.69 M	USA
AbbVie ABBV	64.5 B	$ 264.34	0.09 %	$ 468 B	USA
Humanigen HGEN	25 M	-	-81.12 %	$ 4.28 M	USA
Cocrystal Pharma COCP	1.17 M	$ 1.17	1.74 %	$ 13.2 M	USA
AbCellera Biologics ABCL	137 M	$ 12.7	0.4 %	$ 3.79 B	Canada
Abeona Therapeutics ABEO	7.81 M	$ 5.4	2.65 %	$ 286 M	USA
Collegium Pharmaceutical COLL	4.13 M	$ 22.53	0.2 %	$ 713 M	USA
Corcept Therapeutics Incorporated CORT	5.02 M	$ 116.1	4.93 %	$ 12.1 B	USA
Фармсинтез LIFE	13.2 M	-	-	-	Russia
IGM Biosciences IGMS	38.1 M	-	-	$ 76.9 M	USA
IMV IMV	1.12 M	-	-	$ 13.1 M	Canada
Kinnate Biopharma KNTE	2.28 M	-	-	$ 123 M	USA
Cardiff Oncology CRDF	102 K	$ 1.24	0.74 %	$ 82.9 M	USA
Corbus Pharmaceuticals Holdings CRBP	1.63 M	$ 7.14	0.19 %	$ 95.1 M	USA
Karuna Therapeutics KRTX	13.8 M	-	-	$ 12.2 B	USA
Curis CRIS	428 K	$ 0.83	1.1 %	$ 10.9 M	USA
CorMedix CRMD	586 K	$ 7.85	1.03 %	$ 565 K	USA
Crinetics Pharmaceuticals CRNX	42.1 M	$ 84.95	0.13 %	$ 7.99 B	USA
CRISPR Therapeutics AG CRSP	188 M	$ 54.23	0.23 %	$ 4.88 B	Schweiz
Champions Oncology CSBR	7 K	$ 4.9	0.1 %	$ 67.8 M	USA
Chimerix CMRX	458 K	-	-	$ 756 M	USA
Corvus Pharmaceuticals CRVS	534 K	$ 11.62	8.21 %	$ 918 M	USA
Cue Biopharma CUE	2.29 M	$ 31.41	1.45 %	$ 2.98 B	USA
CEL-SCI Corporation CVM	5.68 M	$ 1.67	2.38 %	$ 13.4 M	USA
Arbutus Biopharma Corporation ABUS	806 K	$ 4.85	0.2 %	$ 929 M	Canada
Cytokinetics, Incorporated CYTK	246 M	$ 64.66	0.17 %	$ 7.77 M	USA
Daré Bioscience DARE	559 K	$ 0.78	4.73 %	$ 8.72 M	USA
Adagene ADAG	1.14 M	$ 2.93	2.86 %	$ 173 M	China
DiaMedica Therapeutics DMAC	4 K	$ 7.94	1.4 %	$ 373 M	USA